Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal metaplasia

Fig. 6

DHA targeting of TPT1 inhibits H. pylori SlyD-induced GIM marker expression. A Three-dimensional molecular structures and binding sites of buclizine hydrochloride, sertraline, and DHA when docked with TPT1. B The binding energy of buclizine hydrochloride, sertraline, and DHA when docked with TPT1. C Western blot for the expression of TPT1 and GIM markers in GES-1 cells treatment with purified HpSlyD proteins (200 ng/mL) for 40 h with or without DHA (10 μM). D Western blot for the expression of TPT1 and GIM markers in AGS cells treatment with purified HpSlyD proteins (200 ng/mL) for 40 h with or without DHA (10 μM). β-tubulin was used as internal loading control. Significance Levels: *P < .05, **P < .01, *** P < .001, ns: non-significant

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us